Skip to main content
. Author manuscript; available in PMC: 2013 Aug 29.
Published in final edited form as: Stem Cells. 2009 Dec;27(12):3112–3120. doi: 10.1002/stem.241

Figure 3.

Figure 3

mBMPCs transplantation improves survival in mouse model of ALI in an α4 and α5 integrins-dependent manner. (A): Schematic time-line for mBMPCs administration and survival assay. (B): mBMPCs improved survival (50%, n = 24), whereas mECs failed to improve survival (0%, n = 18) 24 hours after LPS injection. Irradiation and LPS induced 100% mortality with a median survival time of 12 hours. mBMPCs significantly (p < .001 vs. control 12-hour group) reduced mortality with a median survival time of 48 hours. (C): Lung wet/dry ratios (n = 12–18 per group) were determined after mECs and mBMPCs treatments. Data represent mean ± SEM (n = 18; *, p < .001 vs. control group). (D): Blocking of either α4 integrin or α5 abolished the protective effect of mBMPCs, whereas some protection persisted after blocking of α2 integrin (50%, n = 24; *, p < .001 vs. control group). (E): Lung wet/dry ratios for control (n = 18) and LPS-treated (n = 24) mice were 4.2 ± 0.9 and 9.0 + 1.1, respectively. Blocking of either mBMPCs α5 integrin or α4 integrin failed to prevent pulmonary edema (7.6 ± 1.8; n = 18; *, p < .002 vs. control group), whereas blocking α2 integrin resulted in lung water content of 5.9 ± 1.9 (n = 18). (F): RFP-positive mBMPCs were quantified at 1, 4, and 8 weeks from six sections from six different areas separated by 200 μM intervals. Five fields were selected at random from each section for quantification. Data from three independent experiments are expressed as mean ± SEM. *, p < .001 versus 1 hour. (G–I): Representative lung sections from RFP-positive mBMPCs-treated mice were examined at (G) 1, (H) 4, and (I) 8 weeks by confocal microscopy. One week after mBMPCs treatment (G), lungs contained significantly higher numbers of RFP-positive mBMPCs and a few scattered inflammatory cells, but this number declined by weeks 4 and 8. At week 1, lungs from mBMPCs-treated mice exhibited normal lung architecture and no acute inflammation or edema. Scale bar, 100 μm. For higher resolution images, please see supporting information Figure S6. Abbreviations: ECs, endothelial cells; LPS, lipopolysaccharide; mBMPCs, mouse bone-marrow-derived progenitor cells; RFP, red fluorescent protein.